Oxis Biotech, Inc. (Oxis)

Oncology Corporate Profile

HQ Location

4830 West Kennedy Blvd
Tampa, FL 33609

Company Description

Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, OXS-1550 (DT2219ARL), is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors.

Website: http://www.oxis.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
OXS-1550bispecific scFv recombinant fusion proteinNon-Hodgkin's Lymphoma (NHL)I

View additional information on product candidates here »

Source: http://www.oxis.com

Recent News Headlines

8/21/2017 06:22 am

8/21/2017 06:22 am

8/21/2017 06:22 am

8/21/2017 06:22 am

8/21/2017 06:22 am

8/10/2017 06:19 am

8/10/2017 06:19 am

8/10/2017 06:19 am

8/10/2017 06:19 am

8/10/2017 06:19 am

8/9/2017 06:19 am

8/9/2017 06:19 am

8/9/2017 06:19 am

8/9/2017 06:19 am

8/9/2017 06:19 am

8/7/2017 06:19 am

8/1/2017 06:19 pm

8/1/2017 06:19 pm

8/1/2017 06:19 pm

8/1/2017 06:19 pm

8/1/2017 06:19 pm

7/25/2017 06:19 am

7/5/2017 06:19 am

6/26/2017 06:19 am

6/13/2017 06:19 am